Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Accelerated Phase 1Down Syndrome 1Blast Crisis 1

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3Cyclophosphamide 3ponatinib 2merphos 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Busulfan 2venetoclax 1blinatumomab 1Thiotepa 1Sirolimus 1Rituximab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Injections 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporine 1Cord Blood Stem Cell Transplantation 1Clofarabine 1CT-P10 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Accelerated Phase × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 30 days × Clear all
NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡